Pancreatic Kaposiform Hemangioendothelioma Not Responding to Sirolimus
We report a case of pancreatic KHE associated with KMP and refractory to sirolimus.
Case Report A 4-month-old infant is referred for obstructive jaundice (10 mg/dL conjugated bilirubin) secondary to vascular pancreatic tumor. Magnetic resonance (MR) and immunohistochemistry were compatible with KHE, but the tumor was considered unresectable. We initiated sirolimus (0.8 mg/m2/12 h) to treat KMP, and interventional radiology was performed for percutaneous biliary diversion. This procedure prompted KMP (platelets: 51,000/µL). Sirolimus treatment for 7 days showed no effect; therefore, we started our VAT protocol (vincristine/aspirine/ticlopidin) with great response after 10 days (platelets: 3,70,000/µL). Three months later, percutaneous biliary diversion was replaced by a biliary stent. The tumor disappeared leaving fibrosis and dilatation of biliary tract needing hepaticojejunostomy 6 months later.
Discussion It is difficult to establish protocols for an unusual presentation of a tumor with different targets. This is a reason collaborative multicenter studies should be performed. Management of obstructive jaundice secondary to a tumor that usually regresses in 10 years is an added challenge; therefore, the management should be led by a multidisciplinary team.Sirolimus treatment in cutaneous KHE has been described as successful in the literature, as well as in our own experience; however, it failed in our first patient with visceral KHE. We need to investigate ...
Source: European Journal of Pediatric Surgery Reports - Category: Surgery Authors: Triana, Paloma Junco Dore, Mariela Nu ñez, Vanesa Cerezo Jimenez, Javier Gomez Miguel, Miriam Ferrero D íaz, Mercedes González Ricardo, Joan Novo Andres, Ane Lopez Santamaria, Manuel Lopez-Gutierrez, Juan Carlos Tags: Case Report Source Type: research
More News: Bilirubin | Hemangioendothelioma | Jaundice | Pancreas | Pediatrics | Radiology | Study | Surgery | Thrombocytopenia